These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33407715)

  • 1. Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.
    Vitiello PP; Martini G; Mele L; Giunta EF; De Falco V; Ciardiello D; Belli V; Cardone C; Matrone N; Poliero L; Tirino V; Napolitano S; Della Corte C; Selvaggi F; Papaccio G; Troiani T; Morgillo F; Desiderio V; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2021 Jan; 40(1):15. PubMed ID: 33407715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
    Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
    Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
    [No Abstract]   [Full Text] [Related]  

  • 3. ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer.
    Davis SL; Hartman SJ; Bagby SM; Schlaepfer M; Yacob BW; Tse T; Simmons DM; Diamond JR; Lieu CH; Leal AD; Cadogan EB; Hughes GD; Durant ST; Messersmith WA; Pitts TM
    BMC Cancer; 2022 Oct; 22(1):1107. PubMed ID: 36309653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer.
    Zhang N; Tian YN; Zhou LN; Li MZ; Chen HD; Song SS; Huan XJ; Bao XB; Zhang A; Miao ZH; He JX
    Cell Death Dis; 2021 Feb; 12(2):183. PubMed ID: 33589588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
    Augustine T; Maitra R; Zhang J; Nayak J; Goel S
    Invest New Drugs; 2019 Oct; 37(5):948-960. PubMed ID: 30612311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status.
    Genther Williams SM; Kuznicki AM; Andrade P; Dolinski BM; Elbi C; O'Hagan RC; Toniatti C
    Cancer Cell Int; 2015; 15(1):14. PubMed ID: 25685067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells.
    Sogari A; Rovera E; Grasso G; Mariella E; Reilly NM; Lamba S; Mauri G; Durinikova E; Vitiello PP; Lorenzato A; Avolio M; Piumatti E; Bonoldi E; Aquilano MC; Arena S; Sartore-Bianchi A; Siena S; Trusolino L; Donalisio M; Russo M; Di Nicolantonio F; Lembo D; Bardelli A
    Cell Rep Med; 2024 Feb; 5(2):101376. PubMed ID: 38228147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional mismatch repair and inactive p53 drive sensitization of colorectal cancer cells to irinotecan via the IAP antagonist BV6.
    Tomicic MT; Steigerwald C; Rasenberger B; Brozovic A; Christmann M
    Arch Toxicol; 2019 Aug; 93(8):2265-2277. PubMed ID: 31289894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells.
    Shelton JW; Waxweiler TV; Landry J; Gao H; Xu Y; Wang L; El-Rayes B; Shu HK
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):469-76. PubMed ID: 23540347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic vaccinia virus synergizes with irinotecan in colorectal cancer.
    Ottolino-Perry K; Acuna SA; Angarita FA; Sellers C; Zerhouni S; Tang N; McCart JA
    Mol Oncol; 2015 Oct; 9(8):1539-52. PubMed ID: 26004084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
    Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
    Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.
    Zhang N; Gao Y; Zeng Z; Luo Y; Jiang X; Zhang J; Li J; Zhang J; Gong Y; Xie C
    Clin Transl Oncol; 2021 Sep; 23(9):1827-1837. PubMed ID: 33774805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
    Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK
    Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A carrier-free supramolecular nano-twin-drug for overcoming irinotecan-resistance and enhancing efficacy against colorectal cancer.
    Yuan M; Chen T; Jin L; Zhang P; Xie L; Zhou S; Fan L; Wang L; Zhang C; Tang N; Guo L; Xie C; Duo Y; Li L; Shi L
    J Nanobiotechnology; 2023 Oct; 21(1):393. PubMed ID: 37898773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation.
    Muvaffak A; Coleman KG
    Front Oncol; 2024; 14():1380633. PubMed ID: 38807759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on PARP Inhibitors in Breast Cancer.
    Zimmer AS; Gillard M; Lipkowitz S; Lee JM
    Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer.
    Rimel BJ; Dockery L; Randall LM; Moore K
    Future Oncol; 2020 Nov; 16(33):2701-2711. PubMed ID: 32880196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
    Booth L; Roberts JL; Samuel P; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2018 Jun; 19(6):525-533. PubMed ID: 29405820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
    Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
    Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.